Compare Amgen, Inc. (AMGN) vs HubSpot Inc (HUBS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs HubSpot Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while HubSpot Inc trades at $209.12 (market cap $10.62B). The key difference: Amgen, Inc. is far larger — about 18.5× HubSpot Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals.
| AMGN | HUBS | |
|---|---|---|
Market Cap | $196.12B | $10.62B |
Sector | Health | Technology |
52-Week High | $388.16 | $560.90 |
52-Week Low | $271.18 | $170.39 |
Enterprise Value | $241.41B | $9.18B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
HubSpot (HUBS) trades at $207.48, up 0.74% on the day, showing bullish momentum with strong technical support at $200 and resistance at $213. The company demonstrates robust revenue growth, reaching $3.13 billion in 2025, and has consistently beaten earnings expectations. Analyst sentiment is overwhelmingly positive with an 80.85% buy rating and a consensus price target of $273.53, indicating significant upside potential from current levels.
The outlook for HUBS remains favorable due to accelerating AI integration and customer growth, though high valuation multiples (P/E of 109.2) pose risks if growth slows. Competitive pressures in the CRM space and macroeconomic headwinds could challenge future performance, but strong cash flow generation and expanding margins support a bullish case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
